Skip to main content
SpringerLink
Log in

Connective Tissue Disease Associated Pulmonary Hypertension

  • Chapter
Pulmonary Hypertension

Part of the book series: Contemporary Cardiology™ ((CONCARD))

  • 1567 Accesses

Abstract

Pulmonary hypertension is a common complication of connective tissue disease (CTD) and confers a worse prognosis. Connective tissue disease associated pulmonary hypertension (CTD-PH) occurs most often with systemic sclerosis (SSc) but may also complicate mixed connective tissue disease (MCTD), systemic lupus erythematosus (SLE), and, rarely, rheumatoid arthritis, dermatomysositis/polymyositis, and Sjogren’s syndrome. Although the pathogenesis leading to CTD-PH may vary, the clinical presentation, treatment, and pathological lesions are often similar to those observed in idiopathic pulmonary arterial hypertension (IPAH). This chapter examines the epidemiology, pathophysiology, clinical presentation, and diagnosis of CTD-PH and the evidence supporting the available treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Simonneau G, Galie N, Rubin LJ, Langleben D, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12S.

    PubMed  Google Scholar 

  2. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978; 64(6):998–1004.

    PubMed  CAS  Google Scholar 

  3. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28(4):434–42.

    PubMed  CAS  Google Scholar 

  4. Saito A, Takizawa H, Ito K, Yamamoto K, et al. A case of pulmonary veno-occlusive disease associated with systemic sclerosis. Respirology 2003; 8(3):383–5.

    PubMed  Google Scholar 

  5. Gugnani MK, Pierson C, Vanderheide R, Girgis RE. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: A case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000; 43(3):699–703.

    PubMed  CAS  Google Scholar 

  6. Morassut PA, Walley VM, Smith CD. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992; 8(10):1055–8.

    PubMed  CAS  Google Scholar 

  7. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002; 45(3):225–34.

    PubMed  Google Scholar 

  8. Ungerer RG, Tashkin DP, Furst D, Clements PJ, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75(1):65–74.

    PubMed  CAS  Google Scholar 

  9. Mukerjee D, St George D, Coleiro B, Knight C, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach. Ann Rheum Dis 2003; 62(11):1088–93.

    PubMed  CAS  Google Scholar 

  10. Battle RW, Davitt MA, Cooper SM, Buckley LM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110(6):1515–9.

    PubMed  CAS  Google Scholar 

  11. Pope JE, Lee P, Baron M, Dunne J, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32(7):1273–8.

    PubMed  Google Scholar 

  12. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996; 35(10): 989–93.

    PubMed  CAS  Google Scholar 

  13. Schachna L, Wigley FM, Chang B, White B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124(6): 2098–104.

    PubMed  Google Scholar 

  14. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21(5):467–74.

    PubMed  CAS  Google Scholar 

  15. al Sabbagh MR, Steen VD, Zee BC, Nalesnik M, et al. Pulmonary arterial histology and morphometry in systemic sclerosis: A case-control autopsy study. J Rheumatol 1989; 16(8):1038–42.

    PubMed  CAS  Google Scholar 

  16. Steen V, Medsger TA, Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48(2):516–22.

    PubMed  Google Scholar 

  17. Stupi AM, Steen VD, Owens GR, Barnes EL, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29(4):515–24.

    PubMed  CAS  Google Scholar 

  18. Lee P, Langevitz P, Alderdice CA, Aubrey M, et al. Mortality in systemic sclerosis (scleroderma). Quar J Med 1992; 82(298):139–48.

    CAS  Google Scholar 

  19. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI. et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123(2):344–50.

    PubMed  Google Scholar 

  20. Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31(3):451–64, vi.

    PubMed  Google Scholar 

  21. Hosoda Y, Suzuki Y, Takano M, Tojo T, et al. Mixed connective tissue disease with pulmonary hypertension: A clinical and pathological study. J Rheum 1987; 14(4):826–30.

    PubMed  CAS  Google Scholar 

  22. Esther JH, Sharp GC, Agia GA. Pulmonary hypertension in patients with connective tissue disease and anti-nuclear ribonucleoprotein. Arthritis Rheum 1981; 24:S105.

    Google Scholar 

  23. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63(2):92–107.

    CAS  Google Scholar 

  24. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, et al. Long-term outcome in mixed connective tissue disease: Longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42(5):899–909.

    PubMed  CAS  Google Scholar 

  25. Asherson RA, Morgan SH, Hackett D, Montanes P, et al. Rheumatoid arthritis and pulmonary hypertension. A report of three cases. J Rheum 1985; 12(1):154–9.

    PubMed  CAS  Google Scholar 

  26. Balagopal VP, da Costa P, Greenstone MA. Fatal pulmonary hypertension and rheumatoid vasculitis. Eur Respir J 1995; 8(2):331–3.

    PubMed  CAS  Google Scholar 

  27. Morikawa J, Kitamura K, Habuchi Y, Tsujimura Y, et al. Pulmonary hypertension in a patient with rheumatoid arthritis. Chest 1988; 93(4):876–8.

    PubMed  CAS  Google Scholar 

  28. Young ID, Ford SE, Ford PM. The association of pulmonary hypertension with rheumatoid arthritis. J Rheum 1989; 16(9):1266–9.

    PubMed  CAS  Google Scholar 

  29. Kay JM, Banik S. Unexplained pulmonary hypertension with pulmonary arteritis in rheumatoid disease. Br J Dis Chest 1977; 71(1):53–9.

    PubMed  CAS  Google Scholar 

  30. Dawson JK, Goodson NG, Graham DR, Lynch MP. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000; 39(12):1320–5.

    CAS  Google Scholar 

  31. Baydur A, Mongan ES, Slager UT. Acute respiratory failure and pulmonary arteritis without parenchymal involvement: Demonstration in a patient with rheumatoid arthritis. Chest 1979; 75(4):518–20.

    PubMed  CAS  Google Scholar 

  32. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9(5):338–42.

    PubMed  CAS  Google Scholar 

  33. Shen JY, Chen SL, Wu YX, Tao RQ, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheum Int 1999; 18(4):147–51.

    CAS  Google Scholar 

  34. Li EK, Tam LS. Pulmonary hypertension in systemic lupus erythematosus: Clinical association and survival in 18 patients. J Rheum 1999; 26(9):1923–9.

    PubMed  CAS  Google Scholar 

  35. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheum 1989; 16(7):918–25.

    PubMed  CAS  Google Scholar 

  36. Falcao CA, Alves IC, Chahade WH, Duarte AL, et al. Echocardiographic abnormalities and antiphospholipid antibodies in patients with systemic lupus erythematosus. Arq Bras Cardiol 2002; 79(3):285–91.

    PubMed  Google Scholar 

  37. Robbins IM, Gaine SP, Schilz R, Tapson VF, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117(1):14–8.

    PubMed  CAS  Google Scholar 

  38. Fayemi AO. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 1976; 65(3):284–90.

    PubMed  CAS  Google Scholar 

  39. Schwartzberg M, Lieberman DH, Getzoff B, Ehrlich GE. Systemic lupus erythematosus and pulmonary vascular hypertension. Arch Intern Med 1984; 144(3):605–7.

    PubMed  CAS  Google Scholar 

  40. Sack KE, Bekheit S, Fadem SZ, Bedrossian CW. Severe pulmonary vascular disease in systemic lupus erythematosus. South Med J 1979; 72(8):1016–8.

    PubMed  CAS  Google Scholar 

  41. Nair SS, Askari AD, Popelka CG, Kleinerman JF. Pulmonary hypertension and systemic lupus erythematosus. Arch Intern Med 1980; 140(1):109–11.

    PubMed  CAS  Google Scholar 

  42. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002; 19(3):571–6.

    PubMed  CAS  Google Scholar 

  43. Du L, Sullivan CC, Chu D, Cho AJ, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348(6):500–9.

    PubMed  CAS  Google Scholar 

  44. Kharitonov SA, Cailes JB, Black CM, Du Bois RM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52(12):1051–5.

    PubMed  CAS  Google Scholar 

  45. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, et al. Exhaled nitric oxide in systemic sclerosis: Relationships with lung involvement and pulmonary hypertension. J Rheum 2000; 27(7):1693–8.

    PubMed  CAS  Google Scholar 

  46. Kawaguchi Y, Tochimoto A, Hara M, Kawamoto M, et al. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: Contribution to the transcriptional activity. Arthritis Res Ther 2006; 8(4):R104.

    PubMed  Google Scholar 

  47. Morse J, Barst R, Horn E, Cuervo N, et al. Pulmonary hypertension in scleroderma spectrum of disease: Lack of bone morphogenetic protein receptor 2 mutations. J Rheum 2002; 29(11):2379–81.

    PubMed  Google Scholar 

  48. Yamane K, Miyauchi T, Suzuki N, Yuhara T, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheum 1992; 19(10):1566–71.

    PubMed  CAS  Google Scholar 

  49. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, et al. Circulating endothelin-1 levels in systemic sclerosis subsets—A marker of fibrosis or vascular dysfunction? J Rheum 1994; 21(10):1838–44.

    PubMed  CAS  Google Scholar 

  50. Morelli S, Ferri C, Polettini E, Bellini C, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995; 99(3):255–60.

    PubMed  CAS  Google Scholar 

  51. Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo AM, et al. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis 1991; 50(7):526–7.

    PubMed  CAS  Google Scholar 

  52. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53(8):506–10.

    PubMed  CAS  Google Scholar 

  53. Odoux C, Crestani B, Lebrun G, Rolland C, et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. Am J Respir Crit Care Med 1997; 156(5):1429–35.

    PubMed  CAS  Google Scholar 

  54. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151(3):831–41.

    PubMed  CAS  Google Scholar 

  55. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: Endothelin receptor antagonism. Ann Rheum Dis 2004; 63(9):1009–14.

    PubMed  CAS  Google Scholar 

  56. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003; 5(2):80–93.

    PubMed  CAS  Google Scholar 

  57. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. Curr Opin Rheum 2004; 16(6):723–32.

    CAS  Google Scholar 

  58. Steen VD, Powell DL, Medsger TA, Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31(2):196–203.

    PubMed  CAS  Google Scholar 

  59. Steen VD, Ziegler GL, Rodnan GP, Medsger TA, Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27(2):125–31.

    PubMed  CAS  Google Scholar 

  60. Sacks DG, Okano Y, Steen VD, Curtiss E, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody. J Rheum 1996; 23(4):639–42.

    PubMed  CAS  Google Scholar 

  61. Ulanet DB, Wigley FM, Gelber AC, Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003; 49(1):85–92.

    PubMed  Google Scholar 

  62. Yoshio T, Masuyama J, Sumiya M, Minota S, et al. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheum 1994; 21(11):2058–63.

    PubMed  CAS  Google Scholar 

  63. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheum 1998; 25(3):462–6.

    PubMed  CAS  Google Scholar 

  64. Kuwana M, Kaburaki J, Okano Y, Tojo T, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37(1):75–83.

    PubMed  CAS  Google Scholar 

  65. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, et al. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 1999; 116(1):174–80.

    PubMed  CAS  Google Scholar 

  66. Bordron A, Dueymes M, Levy Y, Jamin C, et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998; 101(10):2029–35.

    PubMed  CAS  Google Scholar 

  67. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98(3):785–92.

    PubMed  CAS  Google Scholar 

  68. Sakao S, Taraseviciene-Stewart L, Wood K, Cool CD, et al. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. Am J Physiol Lung Cell Mol Physiol 2006; 291(3):L362–L368.

    PubMed  Google Scholar 

  69. Filep JG, Bodolay E, Sipka S, Gyimesi E, et al. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 1995; 92(10):2969–74.

    PubMed  CAS  Google Scholar 

  70. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, et al. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003; 284(5):L826–L833.

    PubMed  CAS  Google Scholar 

  71. Humbert M, Monti G, Fartoukh M, Magnan A, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11(3):554–9.

    PubMed  CAS  Google Scholar 

  72. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115(10):2811–21.

    PubMed  Google Scholar 

  73. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145(2):152–3.

    PubMed  Google Scholar 

  74. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353(13):1412–3.

    PubMed  Google Scholar 

  75. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354(25):2667–76.

    PubMed  Google Scholar 

  76. Barst RJ, McGoon M, Torbicki A, Sitbon O, et al. Diagnosis and Differential Assessment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2004; 43:40S–47S.

    PubMed  Google Scholar 

  77. Owens GR, Fino GJ, Herbert DL, Steen VD, et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983; 84(5):546–50.

    PubMed  CAS  Google Scholar 

  78. Steen VD, Graham G, Conte C, Owens G, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35(7):765–70.

    PubMed  CAS  Google Scholar 

  79. Denton CP, Cailes JB, Phillips GD, Wells AU, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheum 1997; 36(2): 239–43.

    CAS  Google Scholar 

  80. Mukerjee D, St George D, Knight C, Davar J, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43(4):461–6.

    CAS  Google Scholar 

  81. McGoon M, Gutterman D, Steen V, Barst R, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl):14S–34S.

    PubMed  Google Scholar 

  82. Nagaya N, Nishikimi T, Uematsu M, Satoh T, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102(8):865–70.

    PubMed  CAS  Google Scholar 

  83. Allanore Y, Borderie D, Meune C, Cabanes L, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003; 48(12):3503–8.

    PubMed  CAS  Google Scholar 

  84. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2):76–81.

    PubMed  CAS  Google Scholar 

  85. Fuster V, Steele PM, Edwards WD, Gersh BJ, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70(4):580–7.

    PubMed  CAS  Google Scholar 

  86. Mariette X, Brenot F, Brouet JC. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjogren’s syndrome and polymyositis. J Rheum 1994; 21(4):772–3.

    PubMed  CAS  Google Scholar 

  87. Morelli S, Giordano M, De Marzio P, Priori R, et al. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993; 2(6):367–9.

    PubMed  CAS  Google Scholar 

  88. Lahaye IE, Rogiers PE, Nagler JM, Chappel R. Vanishing pulmonary hypertension in mixed connective tissue diseas. Clin Rheum 1999; 18(1):45–7.

    CAS  Google Scholar 

  89. Bellotto F, Chiavacci P, Laveder F, Angelini A, et al. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax 1999; 54(4):372–4.

    PubMed  CAS  Google Scholar 

  90. Davas EM, Peppas C, Maragou M, Alvanou E, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheum 1999; 18(6):455–61.

    CAS  Google Scholar 

  91. Karmochkine M, Wechsler B, Godeau P, Brenot F, et al. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 1996; 55(8):561–2.

    PubMed  CAS  Google Scholar 

  92. Groen H, Bootsma H, Postma DS, Kallenberg CG. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: Partial improvement with cyclophosphamide. J Rheum 1993; 20(6):1055–7.

    PubMed  CAS  Google Scholar 

  93. Goupille P, Fauchier L, Babuty D, Fauchier JP, et al. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheum 1994; 21(10):1976–7.

    PubMed  CAS  Google Scholar 

  94. Dahl M, Chalmers A, Wade J, Calverley D, et al. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheum 1992; 19(11):1807–9.

    PubMed  CAS  Google Scholar 

  95. Ferri C, Emdin M, Storino FA, Giuggioli D, et al. Isolated pulmonary hypertension in diffuse cutaneous systemic sclerosis successfully treated with long-term plasma exchange. Scand J Rheum 2000; 29(3):198–200.

    PubMed  CAS  Google Scholar 

  96. Binks M, Passweg JR, Furst D, McSweeney P, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60(6):577–84.

    PubMed  CAS  Google Scholar 

  97. Glikson M, Pollack A, Dresner-Feigin R, Galun E, et al. Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. Chest 1990; 98(3):759–61.

    PubMed  CAS  Google Scholar 

  98. Alpert MA, Pressly TA, Mukerji V, Lambert CR, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991; 68(17):1687–91.

    PubMed  CAS  Google Scholar 

  99. Alpert MA, Pressly TA, Mukerji V, Lambert CR, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102(5):1407–12.

    PubMed  CAS  Google Scholar 

  100. Shinohara S, Murata I, Yamada H, Sato T, et al. Combined effects of diltiazem and oxygen in pulmonary hypertension of mixed connective tissue disease. J Rheum 1994; 21(9):1763–5.

    PubMed  CAS  Google Scholar 

  101. Sfikakis PP, Kyriakidis MK, Vergos CG, Vyssoulis GP, et al. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am J Med 1991; 90(5):541–6.

    PubMed  CAS  Google Scholar 

  102. Klings ES, Hill NS, Ieong MH, Simms RW, et al. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999; 42(12):2638–45.

    PubMed  CAS  Google Scholar 

  103. Badesch DB, Abman SH, Ahearn GS, Barst RJ, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1 Suppl):35S–62S.

    Google Scholar 

  104. Strange C, Bolster M, Mazur J, Taylor M, et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000; 118(4):1077–82.

    PubMed  CAS  Google Scholar 

  105. Humbert M, Sanchez O, Fartoukh M, Jagot JL, et al. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). Chest 1998; 114(1 Suppl):80S–82S.

    PubMed  CAS  Google Scholar 

  106. Badesch DB, Tapson VF, McGoon MD, Brundage BH, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132(6):425–34.

    PubMed  CAS  Google Scholar 

  107. Horn EM, Barst RJ, Poon M. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 118(4):1229–30.

    PubMed  CAS  Google Scholar 

  108. de la MJ, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37(10):1528–33.

    Google Scholar 

  109. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud’s phenomenon: Effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001; 81(4):294–7.

    PubMed  CAS  Google Scholar 

  110. Launay D, Hachulla E, Hatron PY, Goullard L, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheum 2001; 28(10):2252–6.

    PubMed  CAS  Google Scholar 

  111. Olschewski H, Simonneau G, Galie N, Higenbottam T, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347(5):322–9.

    PubMed  CAS  Google Scholar 

  112. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, et al. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 41(2):293–9.

    PubMed  CAS  Google Scholar 

  113. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126(2):420–7.

    PubMed  CAS  Google Scholar 

  114. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest 2006; 129(3):683–8.

    PubMed  Google Scholar 

  115. Rubin LJ, Badesch DB, Barst RJ, Galie N, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12):896–903.

    PubMed  CAS  Google Scholar 

  116. Sitbon O, Badesch DB, Channick RN, Frost A, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest 2003; 124(1):247–54.

    PubMed  CAS  Google Scholar 

  117. Barst RJ, Langleben D, Frost A, Horn EM, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169(4):441–7.

    PubMed  Google Scholar 

  118. Galie N, Badesch D, Oudiz R, Simonneau G, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46(3):529–35.

    PubMed  Google Scholar 

  119. Galie N, Ghofrani HA, Torbicki A, Barst RJ, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20):2148–57.

    PubMed  Google Scholar 

  120. Rosenkranz S, Diet F, Karasch T, Weihrauch J, et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 2003; 139(10):871–3.

    PubMed  Google Scholar 

  121. Rosas V, Conte JV, Yang SC, Gaine SP, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5(3):38–43.

    PubMed  CAS  Google Scholar 

  122. Allcock RJ, O’Sullivan JJ, Corris PA. Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001; 44(7):1660–2.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Kimberly A. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas S. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harrison W. Farber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pulmonary, Critical Care and Sleep Medicine Tufts Medical Center, Boston, MA

    Nicholas S. Hill MD

  2. Pulmonary Center, Boston University, Boston, MA

    Harrison W. Farber MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Fisher, K.A., Hill, N.S., Farber, H.W. (2008). Connective Tissue Disease Associated Pulmonary Hypertension. In: Hill, N.S., Farber, H.W. (eds) Pulmonary Hypertension. Contemporary Cardiology™. Humana Press. https://doi.org/10.1007/978-1-60327-075-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-075-5_8

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-661-0

  • Online ISBN: 978-1-60327-075-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation